We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

LMTX™ in Clinical Trials

News   Sep 22, 2014

 
LMTX™ in Clinical Trials
 
 
Advertisement
 

RELATED ARTICLES

New Technology Transports the Genes for Therapeutic Agents Directly Into Tumor Cells

News

A new technology from UZH researchers enables the body to produce therapeutic agents on demand at exactly the point where they are needed. The innovation could reduce the side effects of cancer therapy and help better deliver COVID-19 treatments to the lungs.

READ MORE

Improving the Quality and Safety of Heparin

News

A team has analyzed Heparin, the blood-thinning drug, using a new method to that can pinpoint contaminants more accurately and quickly, providing greater quality control and safety.

READ MORE

CABYR Isoforms As Targets for Specific Immunotherapy

News

Calcium-binding tyrosine phosphorylation-regulated protein (CABYR) is considered a cancer testis protein. Researchers evaluate the CABYR isoforms: a/b and c mRNA expression in colorectal cancer to determine if these proteins hold promise as vaccine targets.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE